In a study on pediatric r/r Burkitt lymphoma cases, the incidence of grade 3–4 CRS and ICANS after treatment with mouse-derived CD19 CAR T cells were 34.8% and 24.1%, respectively (24). This evidence concerns the gene CD19 and Burkitt lymphoma.